Tumor Profiling For Hereditary Cancer and Somatic Mutations
Genetic Testing Provides Early Detection and Targeted Screening Reduces Advanced Cancer Risk and Might Save Lives. Early Detection is One of the Most Important Things That can Protect Patients’ Health.
Genetic testing can help determine if your patient has an increased risk for certain types of cancer, such as breast, ovarian, colorectal, gastric, pancreatic, prostate, renal, skin, thyroid, uterine cancers or PGL/PCC/GIST adenomas.
Our medical and genetic experts can help determine which genetic testing is right to analyze the risk for hereditary cancer syndromes. After testing, result evaluation and specific recommendations for each
individual case are necessary to decide on further steps for full patient care.
Genetic testing for hereditary cancers analyzes DNA to detect specific, inheritable, disease-related gene mutations that may increase the risk of certain cancers. It provides an in-depth cancer risk assessment for an individual patient.
Hereditary cancers genetic testing at CENTOGENE includes:
Genetic testing: After a specific genetic test is selected a small blood sample is necessary, which allows thorough genetic analysis to look for a change or mutation in the selected genes. Insurance companies typically cover the cost of testing if there is a personal or family history of hereditary cancer.
- Following testing, a comprehensive report is issued based on the test results and the patient’s family history.
- For patients who have a specifically identified gene mutation and a higher risk of cancer, prevention
options, which can include surveillance or prevention tactics are suggested.
- This information from genetic counseling and testing enables family members to make decisions that could save their lives. It also can tell family members that they do not have the mutated gene.
Benefits of Genetic Counseling and Testing
- Elimination of uncertainty
- Understanding cancer risk
- Making informed medical and lifestyle decisions
- Providing helpful information to other family members
Eventual disadvantages/risks of Genetic Counseling and Testing
- Difficulty coping with cancer risk
- Negative impact on family and personal relationships
- Concern about the privacy of results
Why choose CENTOGENE´s hereditary cancer panels?
- Excellent analysis using the most advanced NGS technology
- Shortest turnaround times
- Highest level of quality/accuracy
- Affordable prices
- Experienced medical expertise in the interpretation of complicated cases
- CAP and CLIA and ISO certification and accreditation
Methodological summary of CENTOGENE’s hereditary cancer panels:
- Bi-directional NGS sequencing for all genes included in the panels (listed here below).
- NGS panel analysis with complete 100% coverage for the target regions (technical accuracy of <98.1%).
- For every panel gene, the complete coding sequence, exon/intron boundaries 10 bp into the intron,
relevant promoter gene regions and all HGMD described pathogenic variants are analyzed, with
subsequent variant validation for any clinically relevant genetic variant detected.
CENTOGENE´s hereditary cancer panels:
- BRCA1/BRCA2 panel (genes: BRCA1, BRCA2)
- Breast ovarian cancer panel (genes: CDH1, PTEN, STK11, TP53) Breast ovarian cancer panel PLUS (genes: ATM, BARD1, BRIP1, CHEK2, MEN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, RAD50, RAD51C, RAD51D, XRCC2)
- CentoBreast™ (hereditary breast cancer) (genes: BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C)
- CentoCancer™ (genes: APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NBN, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53)
- CentoColon extended
- Colon cancer non-polyposis panel (genes: MSH2, MLH1, MSH6, PMS2, EPCAM)
- Colon cancer with polyps panel (genes: APC, BMPR1A, MUTYH, PTEN, SMAD4, STK11)
- Ovarian cancer panel, targeted (genes: BARD1, BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MRE11A, MSH2, MSH6, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, STK11, TP53)
- Gastric cancer panel, targeted (genes: BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2, SMAD4)
- Multiple endocrine neoplasias / paraganglioma / pheochromocytoma panel (genes: CDKN1B, MAX, MEN1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL)
- Pancreatic cancer panel, targeted (genes: APC, ATM, BMPR1A, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS1, PMS2, PRSS1, SMAD4, STK11)
- Prostate cancer panel (genes: BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN, PTEN, TP53)
- Renal cancer panel, targeted (genes: EPCAM, FH, FLCN, HNF1A, HNF1B, MET, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN, SDHB, SDHD, TSC1, TSC2, VHL, WT1)
- Skin cancer panel, targeted (genes: CDKN2A, EPCAM, MC1R, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, POT1, PTCH1, XRCC3)
- Thyroid cancer panel, targeted (genes: APC, PTEN, RET)
- Uterine cancer panel, targeted (genes: EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN)
- PGL / PCC / GIST panel, targeted (genes: GDNF, KIF1B, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, TP53, VHL)
- In addition the Comprehensive hereditary cancer panel, screening panel including a high number of
hereditary cancer related genes with ~93,5% coverage is offered (ALK, APC, ATM, BAP1, BLM, BMPR1A, BRIP1, CDC73, CDH1, CDK4, CDKN2A, CEBPA, CHEK2, CYLD, DDB2, DICER1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCC, FANCD2, FANCF, FANCG, FH, FLCN, GATA2, GDNF, HNF1A, HRAS, KIT, MEN1, MET, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NSD1, PALB2, PAX5, PDGFRA, PHOX2B, PMS1, PMS2, POT1, PRKAR1A, PTCH1, PTEN, RB1, RECQL4, RET, RUNX1, SBDS, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCB1, STK11, SUFU, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC)